8.3.4: Hormone antagonists

Part of chapter 8 Malignant Disease and Immunosuppression, section 8.3 Sex hormones and hormone antagonists in malignant disease

High-level prescribing trends for Hormone antagonists (BNF section 8.3.4) across Farrier House Surgery for the last five years. You can explore prescribing trends for this section by Sub-ICB Location, or learn more about this site.

View all matching dm+d items.

No prescriptions found.

Do you need help with your analysis? Don't forget to check the FAQ page, and get in touch if you have questions.

Chemicals

Abiraterone (0803042T0)
Anastrozole (0803041B0)
Apalutamide (0803042V0)
Bicalutamide (0803042A0)
Buserelin (0803042B0)
Cyproterone acetate (0803042E0)
Degarelix (0803042R0)
Enzalutamide (0803042U0)
Exemestane (0803041C0)
Flutamide (0803042H0)
Fulvestrant (0803041AA)
Goserelin acetate (0803042K0)
Histrelin acetate (0803042Q0)
Lanreotide (0803043P0)
Letrozole (0803041L0)
Leuprorelin acetate (0803042N0)
Octreotide acetate (0803043N0)
Pasireotide (0803043Q0)
Relugolix (0803042X0)
Tamoxifen citrate (0803041S0)
Toremifene citrate (0803041U0)
Triptorelin (0803042W0)
Triptorelin acetate (0803042P0)
Triptorelin embonate (0803042S0)
Feedback